Alice Costa

Dr. Alice Costa

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
MSMaura Sonego
Maura Sonego
IPIlenia Pellarin
Ilenia Pellarin
ACAlice Costa
Alice Costa
GVGian Luca Rampioni Vinciguerra
Gian Luca Rampioni Vinciguerra
MCMichela Coan
Michela Coan
Gustavo BaldassarreGustavo Baldassarre
Gustavo Baldassarre
Snail is a target of USP1 that links platinum response to metastasis in ovarian cancer.

12 November 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
ACAlice Costa
Alice Costa
LGLivia Gozzellino
Livia Gozzellino
Milena UrbiniMilena Urbini
Milena Urbini
VIValentina Indio
Valentina Indio
MNMargherita Nannini
Margherita Nannini
Gianandrea PasquinelliGianandrea Pasquinelli
Gianandrea Pasquinelli
The Serum Response Factor (SRF) is a transcription factor that regulates the expression of a wide set of genes involved in cell proliferation, migration, cytoskeletal organization and myogenesis. Accumulating evidence suggests that SRF may play a role in carcinogenesis and tumor progression in various neoplasms, where it is often involved in different fusion events. Here we investigated SRF rearrangements in soft tissue tumors, along with a gene expression profile analysis to gain insight into the oncogenic mechanism driven by SRF fusion. Whole transcriptome analysis of cell lines transiently overexpressing the SRF::E2F1 chimeric transcript uncovered the specific gene expression profile driven by the aberrant gene fusion, including overexpression of SRF-dependent target genes and of signatures related to myogenic commitment, inflammation and immune activation. This result was confirmed by the analysis of two cases of myoepitheliomas harboring SRF::E2F1 fusion with respect to EWSR1-fusion positive tumors. The recognition of the specific gene signature driven by SRF rearrangement in soft tissue tumors could aid the molecular classification of this rare tumor entity and support therapeutic decisions.

11 February 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
ACAlice Costa
Alice Costa
Annalisa AstolfiAnnalisa Astolfi
Annalisa Astolfi
LGLivia Gozzellino
Livia Gozzellino
MNMargherita Nannini
Margherita Nannini
Gianandrea PasquinelliGianandrea Pasquinelli
Gianandrea Pasquinelli
MPmaria pantaleo
maria pantaleo
Uterine mesenchymal tumors (UMTs) are the second most common type of tumors within the uterus corpus after endometrial carcinomas. Among the UMTs, smooth muscle neoplasms are the most common subtype, followed by endometrial stromal sarcoma (ESS). ESSs are uncommon malignancies characterized by molecular heterogeneity and an aggressive behavior. Their management poses significant challenges, particularly for high-grade subtypes. Surgery is the primary intervention for localized disease, while the role of adjuvant therapies, including radiation and chemotherapy, must be better investigated. Hormonal therapy has shown efficacy in low-grade cases but limited success in high-grade tumors. Recent advancements in molecular profiling have revealed potential targets, offering promise for personalized treatments. However, novel therapeutic strategies are urgently needed to improve patient outcomes, particularly for advanced and recurrent disease. This review offers a perspective on the possible novel therapeutic approaches based on the most recent molecular analyses performed on endometrial stromal sarcomas.

Verified
Journal Article
Open access
PDF file
CCCarmen Ciavarella
Carmen Ciavarella
IMIlenia Motta
Ilenia Motta
FVFrancesco Vasuri
Francesco Vasuri
TPTeresa Palumbo
Teresa Palumbo
Anthony Paul LisiAnthony Paul Lisi
Anthony Paul Lisi
Gianandrea PasquinelliGianandrea Pasquinelli
Gianandrea Pasquinelli
The failure of arteriovenous fistulas (AVFs) following intimal hyperplasia (IH) increases morbidity and mortality rates in patients undergoing hemodialysis for chronic kidney disease. The peroxisome-proliferator associated receptor (PPAR-γ) may be a therapeutic target in IH regulation. In the present study, we investigated PPAR-γ expression and tested the effect of pioglitazone, a PPAR-γ agonist, in different cell types involved in IH. As cell models, we used Human Endothelial Umbilical Vein Cells (HUVEC), Human Aortic Smooth Muscle Cells (HAOSMC), and AVF cells (AVFCs) isolated from (i) normal veins collected at the first AVF establishment (T0), and (ii) failed AVF with IH (T1). PPAR-γ was downregulated in AVF T1 tissues and cells, in comparison to T0 group. HUVEC, HAOSMC, and AVFC (T0 and T1) proliferation and migration were analyzed after pioglitazone administration, alone or in combination with the PPAR-γ inhibitor, GW9662. Pioglitazone negatively regulated HUVEC and HAOSMC proliferation and migration. The effect was antagonized by GW9662. These data were confirmed in AVFCs T1, where pioglitazone induced PPAR-γ expression and downregulated the invasive genes SLUG, MMP-9, and VIMENTIN. In summary, PPAR-γ modulation may represent a promising strategy to reduce the AVF failure risk by modulating cell proliferation and migration.

6 January 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
LGLivia Gozzellino
Livia Gozzellino
MNMargherita Nannini
Margherita Nannini
CPCarmine Pizzi
Carmine Pizzi
OLOrnella Leone
Ornella Leone
BCBarbara Corti
Barbara Corti
Annalisa AstolfiAnnalisa Astolfi
Annalisa Astolfi
Primary cardiac sarcomas are considered rare malignant entities associated with poor prognosis. In fact, knowledge regarding their gene signature and possible treatments is still limited. In our study, whole-transcriptome sequencing on formalin-fixed paraffin-embedded (FFPE) samples from one cardiac osteosarcoma and one cardiac leiomyosarcoma was performed, to investigate their mutational profiles and to highlight differences and/or similarities to other cardiac histotypes. Both cases have been deeply detailed from a pathological point of view. The osteosarcoma sample presented mutations involving ATRX, ERCC5, and COL1A1, while the leiomyosarcoma case showed EXT2, DNM2, and PSIP1 alterations. Altered genes, along with the most differentially expressed genes in the leiomyosarcoma or osteosarcoma sample versus the cardiac angiosarcomas and intimal sarcomas (e.g., YAF2, PAK5, and CRABP1), appeared to be associated with cell growth, proliferation, apoptosis, and the repair of DNA damage, which are key mechanisms involved in tumorigenesis. Moreover, a distinct gene expression profile was detected in the osteosarcoma sample when compared to other cardiac sarcomas. For instance, WIF1, a marker of osteoblastic differentiation, was upregulated in our bone tumor. These findings pave the way for further studies on these entities, in order to identify targeted therapies and, therefore, improve patients’ prognoses.

17 February 2026 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Open access
MNMargherita Nannini
Margherita Nannini
LGLivia Gozzellino
Livia Gozzellino
ACAlice Costa
Alice Costa
MNMaria Concetta Nigro
Maria Concetta Nigro
Dario de BiaseDario de Biase
Dario de Biase
MPmaria pantaleo
maria pantaleo
Gastrointestinal stromal tumors (GISTs) are widely regarded as a paradigm of precision oncology, primarily due to their well-characterized molecular drivers and the availability of effective targeted therapies. Thus, GISTs represent an ideal candidate for personalized approaches leveraging liquid biopsy. Liquid biopsy allows the detection of tumor-derived biomarkers containing genomic information in body fluids, mainly blood: circulating tumor cells, circulating free DNA and RNA, circulating tumor DNA, tumor-derived extracellular vesicles, exosomes and tumor-educated platelets. Moreover this technique offers significant advantages compared to tissue biopsy, including reduced invasiveness, faster turnaround times, lower costs and, consequently, repeatability. All these features contribute to making liquid biopsy ideal for several clinical applications, such as real-time monitoring of treatment efficacy and onset of resistance mutations. Accumulating evidence over the years has supported the application of liquid biopsy in GIST patients, culminating in its inclusion in large clinical trials. Therefore, the aim of this review is to critically evaluate the advantages and limitations of liquid biopsy technologies in the context of GIST research to highlight current challenges and guide improvements in future studies.